Search research articles
Contact Us
Filters
Showing results (21-30 of 50) with videos related to
Page
of 5
Sort By:
AJNR. American Journal of Neuroradiology
|
September 1, 1988
MR imaging of spinal cord arteriovenous malformations at 0.5 T: study of 34 cases
D Dormont, F Gelbert, E Assouline, et al.
Revue Neurologique
|
January 1, 1994
[GM2-Gangliosidosis variant B1 disclosed during adolescence by an isolated multi-systemic involvement of the central and peripheral nervous systems]
P Le Coz, E Assouline, M T Vanier, et al.
Ebiomedicine
|
February 4, 2018
Metabolomic Profiling Reveals Cellular Reprogramming of B-Cell Lymphoma by a Lysine Deacetylase Inhibitor through the Choline Pathway
Benet Pera, Jan Krumsiek, Sarit E Assouline, et al.
Techniques in Coloproctology
|
August 29, 2023
Minimally invasive colectomies can be performed with similar outcomes to open counterparts for colorectal cancer emergencies: a propensity score matching analysis utilizing ACS-NSQIP
J Chang, E Assouline, K Calugaru, et al.
Blood
|
March 23, 2012
A phase 1 study of obinutuzumab induction followed by 2 years of maintenance in patients with relapsed CD20-positive B-cell malignancies
Laurie H Sehn, Sarit E Assouline, Douglas A Stewart, et al.
Leukemia & Lymphoma
|
October 16, 2012
A phase I/II study of sorafenib in combination with low dose cytarabine in elderly patients with acute myeloid leukemia or high-risk myelodysplastic syndrome from the National Cancer Institute of Canada Clinical Trials Group: trial IND.186
David A Macdonald, Sarit E Assouline, Joseph Brandwein, et al.
Plos One
|
August 8, 2013
Telomerase contributes to fludarabine resistance in primary human leukemic lymphocytes
May Shawi, Tsz Wai Chu, Veronica Martinez-Marignac, et al.
Blood Cancer Journal
|
October 18, 2014
Phase 1 dose-escalation study of IV ixazomib, an investigational proteasome inhibitor, in patients with relapsed/refractory lymphoma
S E Assouline, J Chang, B D Cheson, et al.
British Journal of Haematology
|
April 26, 2017
A phase 2 study of mocetinostat, a histone deacetylase inhibitor, in relapsed or refractory lymphoma
Connie L Batlevi, Michael Crump, Charalambos Andreadis, et al.
Current Medical Research and Opinion
|
October 8, 2024
Patient-reported outcomes in patients with relapsed or refractory follicular lymphoma treated with zanubrutinib plus obinutuzumab versus obinutuzumab monotherapy: results from the ROSEWOOD trial
Judith Trotman, Pier Luigi Zinzani, Yuqin Song, et al.
Page
of 5
Search research articles
Search
Showing results (21-30 of 50) with videos related to
Sort By:
Page
of 5
AJNR. American Journal of Neuroradiology
|
September 1, 1988
MR imaging of spinal cord arteriovenous malformations at 0.5 T: study of 34 cases
D Dormont, F Gelbert, E Assouline, et al.
Revue Neurologique
|
January 1, 1994
[GM2-Gangliosidosis variant B1 disclosed during adolescence by an isolated multi-systemic involvement of the central and peripheral nervous systems]
P Le Coz, E Assouline, M T Vanier, et al.
Ebiomedicine
|
February 4, 2018
Metabolomic Profiling Reveals Cellular Reprogramming of B-Cell Lymphoma by a Lysine Deacetylase Inhibitor through the Choline Pathway
Benet Pera, Jan Krumsiek, Sarit E Assouline, et al.
Techniques in Coloproctology
|
August 29, 2023
Minimally invasive colectomies can be performed with similar outcomes to open counterparts for colorectal cancer emergencies: a propensity score matching analysis utilizing ACS-NSQIP
J Chang, E Assouline, K Calugaru, et al.
Blood
|
March 23, 2012
A phase 1 study of obinutuzumab induction followed by 2 years of maintenance in patients with relapsed CD20-positive B-cell malignancies
Laurie H Sehn, Sarit E Assouline, Douglas A Stewart, et al.
Leukemia & Lymphoma
|
October 16, 2012
A phase I/II study of sorafenib in combination with low dose cytarabine in elderly patients with acute myeloid leukemia or high-risk myelodysplastic syndrome from the National Cancer Institute of Canada Clinical Trials Group: trial IND.186
David A Macdonald, Sarit E Assouline, Joseph Brandwein, et al.
Plos One
|
August 8, 2013
Telomerase contributes to fludarabine resistance in primary human leukemic lymphocytes
May Shawi, Tsz Wai Chu, Veronica Martinez-Marignac, et al.
Blood Cancer Journal
|
October 18, 2014
Phase 1 dose-escalation study of IV ixazomib, an investigational proteasome inhibitor, in patients with relapsed/refractory lymphoma
S E Assouline, J Chang, B D Cheson, et al.
British Journal of Haematology
|
April 26, 2017
A phase 2 study of mocetinostat, a histone deacetylase inhibitor, in relapsed or refractory lymphoma
Connie L Batlevi, Michael Crump, Charalambos Andreadis, et al.
Current Medical Research and Opinion
|
October 8, 2024
Patient-reported outcomes in patients with relapsed or refractory follicular lymphoma treated with zanubrutinib plus obinutuzumab versus obinutuzumab monotherapy: results from the ROSEWOOD trial
Judith Trotman, Pier Luigi Zinzani, Yuqin Song, et al.
Page
of 5